A new partnership between Premier Research Group and Octagon Research Solutions will expand the companies' solution sets.
Philadelphia, PA-April 29, 2008-Premier Research Group (www.premier-research.com), the international pharmaceutical services group, and Octagon Research Solutions ( www.octagonresearch.com), a leader in the electronic transformation of clinical R&D in the life sciences industry, today announce the formalization of a partnership agreement to provide a broader solution set.
This new partnership combines Octagon’s expertise in electronic submissions with Premier Research’s extensive clinical expertise across a wide array of therapeutic areas. The partnership enables Premier Research to offer Octagon’s electronic submission capabilities as part of its Regulatory Affairs services and for Octagon to offer Premier’s regulatory development and scientific strategy.
James Ottinger, vice president of global consulting and compliance for Premier Research noted, “Our partnership with Octagon broadens our services by offering Octagon’s proven expertise in the technical aspects of electronic submissions while we continue to focus on our core strengths of regulatory strategy and consulting. We are pleased to be working with an organization that also values our deep commitment to being a ‘solution provider’ for our clients.”
“Premier Research has a solid history of consistent, quality delivery that aligns with our own high standard of operation. We believe that the collaboration will ultimately provide a strong product for our valued customers,” commented Jim Walker, chairman and chief excutive officer, Octagon Research Solutions.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.